Tomas Lugo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomas Lugo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Thu Annelise Nguyen
School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA
2 shared publications Kayden Tanner
School of Veterinary Medicine, Texas Tech University
1 shared publication- Kayden Tanner
Texas Tech School of Veterinary Medicine Amarillo Texas USA
1 shared publication Marshall Mays
School of Veterinary Medicine, Texas Tech University
1 shared publication- Marshall Mays
School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA
1 shared publication - Stephanie L. Myers
School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA
1 shared publication
Latest Publications
- Open Access
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1802456
Evaluating the synergistic effects of cisplatin and tamoxifen in canine osteosarcoma cells
Introduction: Canine osteosarcoma is an aggressive primary bone tumor with a high metastatic rate and poor long-term prognosis. Therapeutic resistance remains a major cause of treatment failure. In human osteosarcoma, sex hormones influence tumor survival and proliferation, and emerging evidence suggests a similar role in canine osteosarcoma. Tamoxifen, a selective estrogen receptor modulator, inhibits estrogen receptor signaling and also exhibits estrogen-independent effects, including suppression of multidrug resistance pathways. Cisplatin is commonly used in canine osteosarcoma treatment; however, resistance limits its effectiveness. Therefore, we hypothesized that tamoxifen could enhance cisplatin efficacy through estrogen-independent mechanisms. Methods: Canine osteosarcoma cells were treated with a matrix of tamoxifen and cisplatin concentrations. Cell viability was assessed at 12, 24, and 48 hours using metabolic assays. Cleaved caspase activation and apoptosis-inducing factor expression were evaluated as markers of cell death, while Cyclin D1 and Ki-67 were assessed as markers of cell proliferation. Drug interaction was analyzed using the Zero Interaction Potency model. Results: Synergy analysis at 24 hours demonstrated strong synergistic activity between tamoxifen and cisplatin, with a ZIP score of 16.82. Combination treatment reduced metabolic activity and activated apoptotic markers at lower drug concentrations compared with either treatment alone. Although estrogen receptor expression was confirmed, the enhanced cytotoxic effect of tamoxifen appeared to be largely mediated through estrogen-independent mechanisms. Discussion: These findings suggest that tamoxifen enhances cisplatin-based combination therapy by promoting cell death in canine osteosarcoma at reduced drug concentrations. Combination therapies targeting estrogen-independent pathways may represent a promising strategy for improving treatment response in metastatic canine osteosarcoma and warrant further investigation.
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1802456
Open AccessEvaluating the synergistic effects of cisplatin and tamoxifen in canine osteosarcoma cells
Introduction: Canine osteosarcoma is an aggressive primary bone tumor with a high metastatic rate and poor long-term prognosis. Therapeutic resistance remains a major cause of treatment failure. In human osteosarcoma, sex hormones influence tumor survival and proliferation, and emerging evidence suggests a similar role in canine osteosarcoma. Tamoxifen, a selective estrogen receptor modulator, inhibits estrogen receptor signaling and also exhibits estrogen-independent effects, including suppression of multidrug resistance pathways. Cisplatin is commonly used in canine osteosarcoma treatment; however, resistance limits its effectiveness. Therefore, we hypothesized that tamoxifen could enhance cisplatin efficacy through estrogen-independent mechanisms. Methods: Canine osteosarcoma cells were treated with a matrix of tamoxifen and cisplatin concentrations. Cell viability was assessed at 12, 24, and 48 hours using metabolic assays. Cleaved caspase activation and apoptosis-inducing factor expression were evaluated as markers of cell death, while Cyclin D1 and Ki-67 were assessed as markers of cell proliferation. Drug interaction was analyzed using the Zero Interaction Potency model. Results: Synergy analysis at 24 hours demonstrated strong synergistic activity between tamoxifen and cisplatin, with a ZIP score of 16.82. Combination treatment reduced metabolic activity and activated apoptotic markers at lower drug concentrations compared with either treatment alone. Although estrogen receptor expression was confirmed, the enhanced cytotoxic effect of tamoxifen appeared to be largely mediated through estrogen-independent mechanisms. Discussion: These findings suggest that tamoxifen enhances cisplatin-based combination therapy by promoting cell death in canine osteosarcoma at reduced drug concentrations. Combination therapies targeting estrogen-independent pathways may represent a promising strategy for improving treatment response in metastatic canine osteosarcoma and warrant further investigation.
- Open Access
Genomics in Equine MEED: Whole-Genome Sequencing and Target Mutation Identification
Multisystemic eosinophilic epitheliotropic disease (MEED) is a rare and severe equine disorder characterized by chronic eosinophilic inflammation, epithelial disruption, and multi-organ involvement, with an undefined genetic basis. We performed the high-depth (~40×) whole-genome sequencing of an affected horse and compared it to 40 control genomes. Over 6.3 million variants were identified, with moderate- and high-impact variants enriched in low-frequency categories, including rare and private variants absent from the controls. The affected horse was dominated by missense mutations, with relatively few high-impact variants, consistent with the distributed protein-altering effects rather than a single highly penetrant mutation. Gene prioritization and pathway analyses highlighted the disruption of cytoskeletal organization, microtubule dynamics, epithelial integrity, and immune regulation. The network analysis further revealed the interconnected structural and inflammatory pathways, suggesting a link between an impaired epithelial barrier function and immune homeostasis. Together, these findings provide the first population genomic insight into MEED and support a model in which cumulative mutations contribute to the epithelial instability and persistent inflammation characteristic of the disease.
Open AccessGenomics in Equine MEED: Whole-Genome Sequencing and Target Mutation Identification
Multisystemic eosinophilic epitheliotropic disease (MEED) is a rare and severe equine disorder characterized by chronic eosinophilic inflammation, epithelial disruption, and multi-organ involvement, with an undefined genetic basis. We performed the high-depth (~40×) whole-genome sequencing of an affected horse and compared it to 40 control genomes. Over 6.3 million variants were identified, with moderate- and high-impact variants enriched in low-frequency categories, including rare and private variants absent from the controls. The affected horse was dominated by missense mutations, with relatively few high-impact variants, consistent with the distributed protein-altering effects rather than a single highly penetrant mutation. Gene prioritization and pathway analyses highlighted the disruption of cytoskeletal organization, microtubule dynamics, epithelial integrity, and immune regulation. The network analysis further revealed the interconnected structural and inflammatory pathways, suggesting a link between an impaired epithelial barrier function and immune homeostasis. Together, these findings provide the first population genomic insight into MEED and support a model in which cumulative mutations contribute to the epithelial instability and persistent inflammation characteristic of the disease.
- Open Access
- 18 September 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (9) , 905
Isolation and Characterization of Equine Lymph Node Endothelial Cells
In vitro models have revolutionized our understanding of biological pathways and mechanisms, offering a viable alternative to direct patient testing. However, there is a significant lack of models for different animals, particularly equine models. This study presents a novel primary cell culture extracted from a 3-year-old horse diagnosed with multisystemic eosinophilic epitheliotropic disease. Tissue samples were collected from lymph nodes at various locations. Growth curves of extracted primary cells were analyzed and the optimal conditions were assessed. Biomarkers, such as CD31, ZO-1, CD79, Beta-catenin, E-cadherin, and LYE-1, were detected using an immunofluorescence assay, indicating that these primary cells are of endothelial origin. Initial whole-genome sequencing was performed to confirm the species’ origin and to identify the number of common variations in comparison with the NIH EquCab3.0 reference genome. For the first time, the establishment of primary equine cells from lymph nodes is reported, and these can be used as an in vitro model for testing drug responses, molecular pathways, and environmental effects.
- 18 September 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (9) , 905
Open AccessIsolation and Characterization of Equine Lymph Node Endothelial Cells
In vitro models have revolutionized our understanding of biological pathways and mechanisms, offering a viable alternative to direct patient testing. However, there is a significant lack of models for different animals, particularly equine models. This study presents a novel primary cell culture extracted from a 3-year-old horse diagnosed with multisystemic eosinophilic epitheliotropic disease. Tissue samples were collected from lymph nodes at various locations. Growth curves of extracted primary cells were analyzed and the optimal conditions were assessed. Biomarkers, such as CD31, ZO-1, CD79, Beta-catenin, E-cadherin, and LYE-1, were detected using an immunofluorescence assay, indicating that these primary cells are of endothelial origin. Initial whole-genome sequencing was performed to confirm the species’ origin and to identify the number of common variations in comparison with the NIH EquCab3.0 reference genome. For the first time, the establishment of primary equine cells from lymph nodes is reported, and these can be used as an in vitro model for testing drug responses, molecular pathways, and environmental effects.